Ono Pharmaceutical Co., Ltd. has selected a compound identified and optimized by Evotec AG, for preclinical development, triggering a milestone payment to Evotec. The research collaboration initiated in March 2008 employs Evotec’s high throughput screening and fragment-based drug discovery platform to identify novel compounds against a protease target, to be further optimized by Ono.   Dr. Mario Polywka, chief operating officer of Evotec, said, “We are extremely pleased that we have collab...